ReviewDrug design, development and therapy2025
Repurposing Artemisinin-Based Drugs from Antimalarial to Pan-Therapeutic: Pharmacological Promise and Therapeutic Challenges.
Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Insight into TPS-d Subfamily: The Evolutionary and Functional Diversity in Gymnosperms.Biomolecules · 2026Review
- Exploring the potential targets and mechanisms of artemisinin in the treatment of diabetic kidney disease using network pharmacology and molecular docking.Functional & integrative genomics · 2026Article
- Jichuan decoction alleviates constipation by inhibiting the PI3K/Akt/mTOR signaling pathway: an integrated network pharmacology and experimental study.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The sourcing of pharmaceutical agents from natural products remains a cornerstone of drug discovery. For millennia, herbal remedies have served as foundational therapeutic interventions, yet their mechanisms of action often remain elusive. Artemisinin (ART, or "Qinghaosu") and its derivatives, collectively known as ARTs, exemplify this paradigm. Originating from traditional Chinese medicine, these well-established antimalarial compounds exhibit potent cytotoxicity, positioning them as promising anti-cancer agents. ARTs operate through multiple cancer cell-intrinsic mechanisms and demonstrate synergistic effects with conventional therapies, even against chemoresistant malignancies. Beyond oncology, the therapeutic portfolio of ART-based drugs is rapidly expanding. This review synthesizes recent advancements in the application of ARTs for treating various cancers, Alzheimer's disease, and reproductive disorders. Furthermore, we explore the frontier of ART drug development, focusing on the rational design of ART-derived molecular hybrids and the engineering of nano-enabled delivery systems. These innovative strategies are pivotal for enhancing anti-cancer efficacy and achieving cancer-specific targeting. Ultimately, this work aims to guide the innovation of ART-based precision medicine, revitalizing the exploration and development of natural products in modern pharmacotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.